MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.130
-0.430
-9.43%
Closed 16:00 02/27 EST
OPEN
4.440
PREV CLOSE
4.560
HIGH
4.440
LOW
4.130
VOLUME
131.96K
TURNOVER
--
52 WEEK HIGH
13.37
52 WEEK LOW
4.280
MARKET CAP
181.54M
P/E (TTM)
-13.7209
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MNOV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNOV stock price target is 20.00 with a high estimate of 22.00 and a low estimate of 18.00.

EPS

MNOV News

More
  • Should You Be Concerned About MediciNova, Inc.'s (NASDAQ:MNOV) Historical Volatility?
  • Simply Wall St. · 9h ago
  • The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
  • Benzinga · 1d ago
  • The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
  • Benzinga · 2d ago
  • MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity
  • Zacks Small Cap Research · 2d ago

Industry

Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-2.83%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MNOV

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
More

Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.